Amy S. Zhou

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.

Taraneh Mirzadegan, Klaus Klumpp, S. Tsing, 2008, Journal of medicinal chemistry.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Micaela B. Reddy, A. Connor, Philip Evans, 2011, Biopharmaceutics & drug disposition.

Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Y. Li, W. Huber, T. Mirzadegan, 2008, Bioorganic & medicinal chemistry letters.

Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase.

Yu Li, Andrew Briggs, Klaus Klumpp, 2008, Bioorganic & medicinal chemistry letters.

Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase.

D. Stefanidis, J. Dunn, Amy S. Zhou, 2008, Bioorganic & medicinal chemistry letters.

Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.

S. Tsing, T. Mirzadegan, S. Harris, 2008, Journal of medicinal chemistry.

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

A. Connor, Philip Evans, M. Reddy, 2011, Biopharmaceutics & drug disposition.